| General Information | |
|---|---|
| ZINC ID | ZINC000045372442 |
| Molecular Weight (Da) | 483 |
| SMILES | CCC(C)(C)NC(=O)c1nn(-c2ccccc2Cl)c(-c2ccc(Cl)cc2)c1Cn1cncn1 |
| Molecular Formula | C24Cl2N6O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 134.794 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| LogP | 4.818 |
| Activity (Ki) in nM | 12.0226 |
| Polar Surface Area (PSA) | 77.63 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.955 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.25 |
| Ilogp | 3.95 |
| Xlogp3 | 5.61 |
| Wlogp | 5.4 |
| Mlogp | 4.04 |
| Silicos-it log p | 4.42 |
| Consensus log p | 4.68 |
| Esol log s | -6.34 |
| Esol solubility (mg/ml) | 0.000223 |
| Esol solubility (mol/l) | 0.00000046 |
| Esol class | Poorly sol |
| Ali log s | -7 |
| Ali solubility (mg/ml) | 0.000048 |
| Ali solubility (mol/l) | 9.93E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.69 |
| Silicos-it solubility (mg/ml) | 0.00000097 |
| Silicos-it solubility (mol/l) | 2.02E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.27 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.6 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.359 |
| Logd | 4.786 |
| Logp | 4.657 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 97.40% |
| Vdss | 1.942 |
| Fu | 2.96% |
| Cyp1a2-inh | 0.484 |
| Cyp1a2-sub | 0.235 |
| Cyp2c19-inh | 0.931 |
| Cyp2c19-sub | 0.178 |
| Cl | 5.148 |
| T12 | 0.161 |
| H-ht | 0.331 |
| Dili | 0.993 |
| Roa | 0.228 |
| Fdamdd | 0.29 |
| Skinsen | 0.396 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.646 |
| Bcf | 1.702 |
| Igc50 | 3.805 |
| Lc50 | 5.613 |
| Lc50dm | 3.664 |
| Nr-ar | 0.001 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.95 |
| Nr-aromatase | 0.989 |
| Nr-er | 0.591 |
| Nr-er-lbd | 0.331 |
| Nr-ppar-gamma | 0.115 |
| Sr-are | 0.887 |
| Sr-atad5 | 0.025 |
| Sr-hse | 0.162 |
| Sr-mmp | 0.853 |
| Sr-p53 | 0.786 |
| Vol | 465.626 |
| Dense | 1.035 |
| Flex | 0.348 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.382 |
| Synth | 2.673 |
| Fsp3 | 0.25 |
| Mce-18 | 25 |
| Natural product-likeness | -1.77 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |